Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: The hallmark of most patients with severe asthma is type 2 inflammation, driven by innate and adaptive immune responses leading to either allergic or non-allergic eosinophilic infiltration of airways. The cellular and molecular pathways underlying severe type 2 asthma can be successfully targeted by specific monoclonal antibodies.
Areas Covered: This review article provides a concise overview of the pathophysiology of type 2 asthma, followed by an updated appraisal of the mechanisms of action and therapeutic efficacy of currently available biologic treatments used for management of severe type 2 asthma. Therefore, all reported information arises from a wide literature search performed on PubMed.
Expert Opinion: The main result of the recent advances in the field of anti-asthma biologic therapies is the implementation of a personalized medicine approach, aimed to achieve clinical remission of severe asthma. Today this accomplishment is made possible by the right choice of the most beneficial biologic drug for the pathologic traits characterizing each patient, including type 2 severe asthma and its comorbidities.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17476348.2024.2380072 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Associations between PM from prescribed burning and emergency department visits in 11 Southeastern US states.
Environ Int
September 2025
Department of Environmental Health, Boston University School of Public Health, 715 Albany Street, Boston, MA 02118, USA. Electronic address:
Longer, more severe wildfire seasons are becoming the norm in fire-prone areas. Prescribed burning is a tool used to mitigate wildfire spread. However, prescribed burning also contributes to air pollution, including PM (particulate matter with aerodynamic diameter <= 2.
View Article and Find Full Text PDFDesigning a patient onboarding in a multidisciplinary severe asthma unit.
Farm Hosp
September 2025
Servicio de Farmacia, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, España.
Objetives: To design the patient onboarding in a multidisciplinary severe asthma unit, according to the needs identified by patients and professionals in the unit.
Methods: Qualitative study using the human-centred design conducted between November 2022 and February 2023. Patients and professionals from the severe asthma unit and experts in the methodology participated.
Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab Registry.
Respir Med
September 2025
Centre of Excellence in Treatable Traits, College of Health, Medicine and Wellbeing, University of Newcastle, New Lambton Heights, NSW, Australia; Asthma and Breathing Research Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia; Department of Respiratory and Sleep Medici
Background: The benefits of oral corticosteroid (OCS) stewardship approaches -including monoclonal antibody treatments for severe asthma- on reducing toxic OCS exposure and related comorbidities such as depression and anxiety require real-world evaluation.
Methods: This real-world observational study investigated OCS exposure and associated complications over 24 months in patients enrolled in the Australian Mepolizumab Registry (n=412).
Results: Patients were median age 59 years, 58% were female.
Emerging systemic treatments for asthma and allergic diseases: New tricks, same dog?
J Allergy Clin Immunol Pract
September 2025
Associate Professor of Medicine, Medical Director of Clinical Asthma Research, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center. Electronic address:
Asthma and allergic diseases are heterogeneous conditions driven by complex immunological pathways, with type 2 (T2) inflammation being a key but not exclusive component. Advances in immunology have spurred interest in a breadth of mechanisms and innovative therapeutic strategies, including novel targets, extended dosing intervals, and combined-target therapies. This clinical commentary provides a critical overview of ongoing clinical trials and emerging evidence supporting the use of these therapies in asthma and other allergic conditions.
View Article and Find Full Text PDFTHE DOSE-RESPONSE OF INHALED CORTICOSTEROIDS IN COMBINATION ICS/LABA MAINTENANCE THERAPY FOR ASTHMA: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Chest
September 2025
Medical Research Institute of New Zealand, Wellington, New Zealand, ; Victoria University of Wellington, Wellington, New Zealand.
Background: High doses of maintenance inhaled corticosteroids (ICS) in asthma may achieve only modest additional clinical benefit beyond low-to-medium doses and are associated with an increased risk of adverse systemic effects. The ICS dose-response relationship when administered as maintenance combination ICS/long-acting beta-agonist (LABA) therapy is uncertain.
Research Question: What is the ICS dose-response of maintenance ICS/LABA therapy?
Methods: A systematic review of randomized controlled trials (RCTs) allocating participants to >1 ICS dose category, per Global Initiative for Asthma categorization, administered in combination ICS/LABA inhalers was conducted.